[Guidelines for prevention of febrile neutropenia].
Neutropenia and febrile neutropenia are common consequences of some cytotoxic chemotherapy regimens. This situation leads to modifications of the therapeutic regimen, conducting to either dose reduction or cycle delays. Granulocyte colony stimulating factors are commonly used to minimize chemotherapy cytotoxic effect on the granulocytic series. The objective of this study is to assess the available evidence in what concerns the efficacy and safety of granulocyte colony stimulating factors, in several settings of their use. An extensive bibliographic review was performed, including clinical trials, observational studies, systematic reviews, and international guidelines for neutropenia prophylaxis, which aims to establish recommendations on their use, in adequacy to the National reality.
Barroso
Sérgio
S
Serviço de Oncologia, Hospital do Espírito Santo, Evora.
Damasceno
Margarida
M
Dinis
José
J
Gervásio
Helena
H
da Luz
Ricardo
R
Passos-Coelho
J L
JL
Sá
Anabela
A
Costa
Luís
L
Rodrigues
Helena
H
Andrade
Sofia
S
Macedo
Ana
A
Moital
Inês
I
D000970:Antineoplastic Agents / Q000009:adverse effects; D005334:Fever / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D017410:Practice Guidelines as Topic
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor